Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropept...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (196 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545526504498 |
---|---|
ctrlnum |
(CKB)5400000000041063 (oapen)https://directory.doabooks.org/handle/20.500.12854/69163 (EXLCZ)995400000000041063 |
collection |
bib_alma |
record_format |
marc |
spelling |
Kuo, Hann-Chorng edt Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (196 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects. English Medicine bicssc urethra onabotulinumtoxinA voiding therapeutic outcome lower urinary tract symptoms botulinum toxin benign prostatic hyperplasia prostatitis inflammation Botulinum toxin chronic prostatitis interstitial cystitis treatment bladder pain botulinum toxin A predictor maximal bladder capacity hydrodistention urethral sphincter urethral sphincter dysfunction urodynamics drug delivery overactive bladder painful bladder syndrome molecular mechanism chronic pelvic pain syndrome pelvic pain functional urology disorder human network meta-analysis OnabotulinumtoxinA peripheral tibial nerve stimulation sacral neuromodulation bladder sensation therapy pathophysiology diabetes mellitus mid-urethral sling antimuscarinics urinary incontinence functional urological disorders pain neurogenic detrusor overactivity 3-03936-670-X 3-03936-671-8 Kuo, Hann-Chorng oth |
language |
English |
format |
eBook |
author2 |
Kuo, Hann-Chorng |
author_facet |
Kuo, Hann-Chorng |
author2_variant |
h c k hck |
author2_role |
Sonstige |
title |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
spellingShingle |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
title_full |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
title_fullStr |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
title_full_unstemmed |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
title_auth |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
title_new |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
title_sort |
botulinum toxin treatment for pain and inflammation in functional urological disorders |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
physical |
1 electronic resource (196 p.) |
isbn |
3-03936-670-X 3-03936-671-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT kuohannchorng botulinumtoxintreatmentforpainandinflammationinfunctionalurologicaldisorders |
status_str |
n |
ids_txt_mv |
(CKB)5400000000041063 (oapen)https://directory.doabooks.org/handle/20.500.12854/69163 (EXLCZ)995400000000041063 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796651990276636672 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03748nam-a2200817z--4500</leader><controlfield tag="001">993545526504498</controlfield><controlfield tag="005">20231214132944.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041063</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69163</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041063</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kuo, Hann-Chorng</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (196 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urethra</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">onabotulinumtoxinA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">voiding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lower urinary tract symptoms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">botulinum toxin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">benign prostatic hyperplasia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Botulinum toxin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic prostatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interstitial cystitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">botulinum toxin A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">maximal bladder capacity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hydrodistention</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urethral sphincter</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urethral sphincter dysfunction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urodynamics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">overactive bladder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">painful bladder syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular mechanism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic pelvic pain syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pelvic pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">functional urology disorder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OnabotulinumtoxinA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">peripheral tibial nerve stimulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sacral neuromodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sensation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathophysiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diabetes mellitus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mid-urethral sling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimuscarinics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urinary incontinence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">functional urological disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurogenic detrusor overactivity</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-670-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-671-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kuo, Hann-Chorng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:37:52 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338010500004498&Force_direct=true</subfield><subfield code="Z">5338010500004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338010500004498</subfield></datafield></record></collection> |